As we demonstrated here that BCL-3-deficient CaSki cells have decreased expression of fibronectin and because mesenchymal markers are not properly expressed on KIAA1199 deficiency in cervical cancer cells, our data defined BCL-3 as an oncogenic protein that promotes EMT, at least by controlling KIAA1199 expression. The gene discussed is CEMIP; the disease is cervical carcinoma.